Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Jalving, M.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(5)
+
-
Availability
Open access
(4)
+
-
Metadata Only
(2)
+
-
Creation Date
2021
(2)
+
-
2023
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(4)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(4)
+
-
Scholarly Publications
(2)
+
-
Author
Jalving, M.
(6)
+
-
Blank, C.U.
(4)
+
-
Veldt, A.A.M. van der
(4)
+
-
Fehrmann, R.S.N.
(3)
+
-
Vries, E.G.E. de
(3)
+
-
Baarle, D. van
(2)
+
-
Bhattacharya, A.
(2)
+
-
Dingemans, A.M.C.
(2)
+
-
Eertwegh, A.J.M. van den
(2)
+
-
Els, C.A.C.M. van
(2)
+
-
Groot, J.W.B. de
(2)
+
-
Haanen, J.B.A.G.
(2)
+
-
Hiltermann, T.J.N.
(2)
+
-
Hospers, G.A.P.
(2)
+
-
Kapiteijn, E.
(2)
+
-
Kvistborg, P.
(2)
+
-
Oosting, S.F.
(2)
+
-
Rimmelzwaan, G.F.
(2)
+
-
Rots, N.Y.
(2)
+
-
Smit, E.F.
(2)
+
-
Suijkerbuijk, K.P.M.
(2)
+
-
Wind, T.T.
(2)
+
-
Show more
Language
en
(6)
+
-
Search results
(1 - 6 of 6)
show grid
show list
save search
Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas
A survival tree of advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition
COVID-19 vaccination: the VOICE for patients with cancer
Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program